The Sick Leave Act 2022 (the “Act”) which provides for a statutory sick pay scheme for employees was signed into law by the Irish President on the 20 July 2022.
This briefing highlights some emerging legal risks associated with hybrid working and considers how employers should plan going forward.
On 12 July 2022, the UK’s Competition and Markets Authority (“CMA”) published its final form Guidance on the new Vertical
Agreements Block Exemption Order (“VABEO”), which came into force on 1 June 2022. The VABEO replaced the retained Vertical Agreements Block Exemption Regulation (“VABER”) which expired on 31 May 2022. Similarly, the CMA Guidance replaces the EU Guidelines on Vertical Restraints (2010) which had applied in the UK.
The UK Government has published its Response Statement following the White Paper published in March 2021 on audit and corporate governance reform.
This guidance is relevant to UK publicly traded companies when planning and conducting their annual general meeting (AGM) and other general meetings (GMs).
The decision is an example of the English Courts’ willingness to develop and apply existing case law to contemporaneous disputes, in this case in relation to crypto assets and persons unknown who might be out of the jurisdiction (a common feature of such cases) to ensure victims have a timely means of tracing and recovering stolen assets.
This article summarises the German Parliament's legislative package on renewable energy, which is regarded as the largest energy policy amendment in decades.
On July 7, 2022, the Centers for Medicare & Medicaid Services (CMS) proposed five new changes to Remote Therapeutic Monitoring (RTM) services under the Medicare program. The changes are part of the proposed 2023 Medicare Physician Fee Schedule rule. To learn more check out this Foley & Lardner article.
On July 7, 2022, the Centers for Medicare and Medicaid Services (CMS) released its proposed 2023 Medicare Physician Fee Schedule (PFS) rule. Learn more about this rule by checking out this article released by Foley and Lardner.
The Centers for Medicare and Medicaid Services (CMS) has announced that it “fully expects” to reverse
Medicare Part B rate cuts for separately payable drugs acquired through the 340B Drug Pricing Program,
resulting in an estimated additional $1.96 billion for 340B hospitals. Learn more through this blog post released by Foley & Lardner.